Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial

Fig. 3

Neoadjuvant therapy-induced changes of biomarkers in tumor tissue. a. Changes of proportion of Ki67-positive tumor cells after neoadjuvant endocrine therapy (NET). b. Changes of proportion of Ki67-positive tumor cells after neoadjuvant chemotherapy (NAC). c. (left) Representative pictures of PD-L1 staining in biopsy samples (Baseline) and surgical samples (Post-treatment) from patients treated with NET. Scale bar: 400×. (right) Scatter plots showed the changes of PDL-1 staining index respectively in tumor cells and immune cells after NET. d. (left) Representative pictures of Foxp3 staining in biopsy samples (Baseline) and surgical samples (Post-treatment) from patients treated with NET. Scale bar: 400×. (right) A scatter plot showed the changes of number of Foxp3-positive cells in tumor tissues after NET. Statistical analyses were performed by Wilcoxon matched-pairs signed rank test and P < 0.05 was considered statistically significant

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us